Valve replacement for failing aortic bioprosthetic valves
Part of Heart & circulation clinical trials.
This trial studies a new “valve-in-valve” procedure to treat a failing aortic bioprosthetic valve. It may help people improve blood flow through the heart valve and reduce valve-related problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a failing bioprosthetic (tissue) valve in the heart’s aortic position
- Your current aortic valve leak and/or blockage is at least moderate
- The old valve size fits a specific range (about 18.5 to 28.5 mm inside)
- Your heart symptoms are at least moderate (NYHA class II or higher)
- Your heart team believes you are low to intermediate risk for this procedure
- You agree to the study and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new version of a heart valve (SAPIEN X4) placed without open-heart surgery. It's for people with severe aortic stenosis who have symptoms like shortness of breath or chest pain.
This study looks at how safe and effective the SAPIEN 3 valve is for patients in China who have a specific type of bicuspid aortic valve (Type-0) that is severely narrowed. If you have severe aortic stenosis and meet the criteria, this treatment might be an option for you.
This study is testing a new heart valve called the SAPIEN 3 Ultra RESILIA valve for people with severe aortic stenosis. Researchers want to see how well it works and how safe it is over 10 years after a minimally invasive valve replacement procedure called TAVI.
This trial studies whether a new transcatheter aortic valve (SAPIEN X4) is safe and works well in people whose previously implanted aortic valve is now failing. It may help reduce valve symptoms in higher-surgery-risk patients who are not good candidates for open-heart valve replacement.
This trial tests a new, less invasive heart valve (called SAPIEN X4) placed through a vein in your leg to replace a failing mitral valve that was previously repaired or replaced. It is for people who are at high risk for open-heart surgery and have a leaky or narrowed mitral valve.
This trial compares two of the newest transcatheter aortic valve devices—the SAPIEN 3 Ultra Resilia and Evolut FX—to see which works better for patients with severe aortic stenosis (a narrowed aortic valve). Both devices are placed through a catheter without open surgery.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.